




BUSINESS & FINANCIAL UPDATE

Q3 2022

November 22, 2022

Forward Looking Statements

The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma S.A., including estimates of target market opportunity, timing of planned clinical trials and results from those trials, regulatory strategy and timing of planned regulatory submissions, manufacturing capabilities and strategy for expansion of the ERYCAPS platform. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimates based upon the information available to ERYTECH Pharma S.A. as of the date of this presentation. The company's expectations regarding the effects of COVID-19 on the Company's trials and development may be incorrect. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements. Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statement.



Business & Financial Update Q3 2022

Introduction and Business Highlights

- Gil Beyen, Chief Executive Officer

Financial Update, Strategic Priorities & Next Steps

- Eric Soyer, Chief Financial & Chief Operating Officer

Questions & Answers

- Gil Beyen, Chief Executive Officer
- Eric Soyer, Chief Financial & Chief Operating Officer
- Iman El Hariry, MD, PhD, Chief Medical Officer

ERYTECH, Leader in Red Blood Cell-based Therapeutics



Clinical stage biopharmaceutical company, founded in 2004 around its proprietary ERYCAPS[®] technology allowing reproducible encapsulation of therapeutics in red blood cells (RBC)



Proof of concept established with eryaspase (Graspa[®]), L-asparaginase established in donor derived RBC. Eryaspase demonstrated safety and encouraging clinical activity in clinical trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer (PAC); development not further pursued following Phase 3 trial in 2L PAC not achieving primary endpoint and new regulatory hurdles in process of seeking approval in ALL



Pipeline of preclinical programs with ERYCAPS[®] platform, including new development with RBC-derived extracellular vesicles (ERYCEV[™]), and rare disease opportunities
Partnership with SQZ Biotech for immuno-modulation approach with RBC



Industrialized production: company operated cGMP facility in Lyon, France (*see appendix*)



HQ in Lyon, France; (virtual) office in Cambridge, MA, US
Listed on Nasdaq and Euronext (Ticker ERYP)
Strategic partnering process ongoing



BLA: Biologics License Application; 1L: First line; 2L: Second line
IST: Investigator-sponsored trial; cGMP: current good manufacturing practice

Business Highlights Q3 2022



- Plans to pursue a BLA submission in hypersensitive ALL stopped following recent feedbacks and additional requests from the FDA
- No evidence of clinical benefit in TRYbeCA-2, Ph 2 clinical trial in triple-negative breast cancer (TNBC) in patients enrolled before early study closure
- Further development of Graspa halted



- Deep restructuring implemented; team size reduced by approximately 75% since start of year



- Promising preclinical development with ERYCEV™, novel red blood cell vesiculation technology, and rare disease programs



- Good progress on strategic review and partnering alternatives



Business & Financial Update Q3 2022

Introduction and Business Highlights

- Gil Beyen, Chief Executive Officer

Financial Update, Strategic Priorities & Next Steps

- Eric Soyer, Chief Financial & Chief Operating Officer

Questions & Answers

- Gil Beyen, Chief Executive Officer
- Eric Soyer, Chief Financial & Chief Operating Officer
- Iman El Hariry, MD, PhD, Chief Medical Officer

Q3 Financial Results – P&L

- Net loss for the first 9 months of 2022 was €6.2 million, a €35.4 million improvement over the same period of last year, related mostly to:
 - €24.4 million net gain on the sale of the Princeton facility,
 - €15.5 million decrease in operating expenses (-33%) year-over-year,
- Total operating expenses of €31.2 million included an impairment provision of €2.5 million on the Lyon production facility, related to the end of eryaspase operations, and a €1.9 million provision for restructuring, related to the resizing of French operations and staff
- Income tax included in 2022 a provision of €3.8 million (\$4.1 million), reflecting the maximum potential tax impacts of the capital gain from the sale of the Princeton facility

<i>In thousands of euros</i>	Q3 2022 (9 months)	Q3 2021 (9 months)
Revenues	—	—
Other income	1 423	3,402
Net gain on asset sale	24,351	—
Operating income	25,774	3,402
Research and development	(20,377)	(34,728)
General and administrative	(10,870)	(12,242)
Operating expenses	(31,248)	(46,770)
Operating income (loss)	(5,474)	(43,368)
Financial income	4,031	4,356
Financial expenses	(881)	(2,570)
Financial income (loss)	3,150	1,786
Income tax	(3,839)	(2)
Net loss	(6,163)	(41,584)

Cash Position and Cash Runway

- As of September 30, 2022: total cash position of €47.3 million (\$46.3 million) compared with €33.7 million (\$38.1 million) on December 31, 2021
- The €13.6 million net increase in cash position in the first 9 months of 2022 was attributable to:
 - €37.6 million from the sale of the Princeton facility
 - €27.4 million net cash utilization in operating and investing activities (excl. the sale of the Princeton facility)
 - €1.6 million cash generated in financing activities
 - Positive \$/€ currency exchange impact of €1.7 million
- Earlier this year, the company initiated a deep restructuring and cost reduction program, then further intensified with the halt of the BLA process. Considering this ongoing reduction in operating expenses, the Company believes that its current cash position can fund its current programs and planned operating expenses to mid-2024.

Key News Flow and Milestones Expected Over the Next 6 Months

- Update on preclinical programs
- Update on strategic review and partnering process



Business & Financial Update Q3 2022

Introduction and Business Highlights


- Gil Beyen, Chief Executive Officer

Financial Update, Strategic Priorities & Next Steps

- Eric Soyer, Chief Financial & Chief Operating Officer

Questions & Answers

- Gil Beyen, Chief Executive Officer
- Eric Soyer, Chief Financial & Chief Operating Officer
- Iman El Hariry, MD, PhD, Chief Medical Officer



Thank you!

ERYTECH Pharma SA
60 Avenue Rockefeller
69008 Lyon
France

erytech 

 Nasdaq

ERYP
LISTED
EURONEXT

ERYTECH Pharma Inc
1 Main Street
Cambridge, MA 02142
USA